Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Viking Thera (VKTX)

Viking Thera (VKTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,773,142
  • Shares Outstanding, K 113,036
  • Annual Sales, $ 0 K
  • Annual Income, $ -109,960 K
  • EBIT $ -275 M
  • EBITDA $ -292 M
  • 60-Month Beta 0.71
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.31

Options Overview Details

View History
  • Implied Volatility 78.76% (+5.18%)
  • Historical Volatility 58.52%
  • IV Percentile 29%
  • IV Rank 18.49%
  • IV High 170.22% on 08/12/25
  • IV Low 58.01% on 09/04/25
  • Expected Move (DTE 1) 1.03 (3.03%)
  • Put/Call Vol Ratio 0.24
  • Today's Volume 11,247
  • Volume Avg (30-Day) 17,957
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 164,193
  • Open Int (30-Day) 241,650
  • Expected Range 32.94 to 35.00

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.89
  • Number of Estimates 11
  • High Estimate -0.82
  • Low Estimate -1.01
  • Prior Year -0.32
  • Growth Rate Est. (year over year) -178.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.54 +15.42%
on 01/13/26
37.83 -9.89%
on 12/24/25
-1.31 (-3.70%)
since 12/22/25
3-Month
29.54 +15.42%
on 01/13/26
43.15 -21.00%
on 11/12/25
+2.67 (+8.50%)
since 10/22/25
52-Week
18.92 +80.18%
on 04/09/25
43.15 -21.00%
on 11/12/25
+0.04 (+0.12%)
since 01/22/25

Most Recent Stories

More News
3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026

These three biotech stocks combine scale, late-stage pipelines, and analyst confidence, giving investors compelling upside potential in 2026

VKTX : 34.13 (+2.25%)
LLY : 1,091.31 (+1.19%)
BIIB : 173.36 (+0.43%)
Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All

As weight loss drugs move from injections to pills, this thematic ETF provides broad exposure for investors looking to profit from the industry’s next leg up.

VKTX : 34.13 (+2.25%)
AZN : 91.72 (+1.30%)
OZEM : 36.81 (+2.00%)
NVO : 62.29 (+5.01%)
LLY : 1,091.31 (+1.19%)
REGN : 755.21 (+0.78%)
AMGN : 348.93 (+1.55%)
PFE : 26.09 (+0.77%)
Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity

Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed

VKTX : 34.13 (+2.25%)
Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity

Study is Evaluating Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens

VKTX : 34.13 (+2.25%)
Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

SAN DIEGO , Jan. 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic...

VKTX : 34.13 (+2.25%)
This Small But Mighty Stock Could Surprise Investors in 2026

This under-the-radar biotech stock is setting up for a big 2026.

VKTX : 34.13 (+2.25%)
Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference

SAN DIEGO , Nov. 25, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic...

VKTX : 34.13 (+2.25%)
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735

78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity

VKTX : 34.13 (+2.25%)
Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025

VENTURE Study Exploratory Analysis Shows VK2735 Improved Cardiometabolic Parameters After 13 Weeks; Reducing Prediabetes and Metabolic Syndrome

VKTX : 34.13 (+2.25%)
Viking Therapeutics to Participate at Upcoming Investor Conferences

SAN DIEGO , Nov. 4, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic...

VKTX : 34.13 (+2.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Viking Therapeutics, Inc. is a biopharmaceutical company. The company is engaged in development of novel therapies for metabolic and endocrine disorders. Its product candidate consists of VK5211, VK0214, VK0612 and VK2809 which are in different clinical trial. Viking Therapeutics, Inc. is based in LA...

See More

Key Turning Points

3rd Resistance Point 35.66
2nd Resistance Point 34.82
1st Resistance Point 34.10
Last Price 34.13
1st Support Level 32.54
2nd Support Level 31.70
3rd Support Level 30.98

See More

52-Week High 43.15
Last Price 34.13
Fibonacci 61.8% 33.89
Fibonacci 50% 31.03
Fibonacci 38.2% 28.18
52-Week Low 18.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar